ApolloMed Q3 revenue up 40% to $317M; net income down to $26M; raises full-year guidance

Astrana Health, Inc.

2022-Q3 EPS reported $1.12 revenue$849,955,000

Q3 revenue $317M (+40% YoY); net income $26M vs $34.3M; diluted EPS $0.56 vs $0.74.
Adjusted EBITDA $57.1M (revised calculation) vs $62.9M prior year; nine-month revenue $850M (+47%).
Closed acquisition of All American Medical Group (Oct 31) adding >15,000 members; acquired Valley Oaks Medical Group (9 clinics) serving 20,000 patients.
Raised FY2022 revenue guidance to $1.095-1.115B, net income to $50.5-67M, EBITDA to $107.5-133.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Astrana Health, Inc. reported nine months ended September 30, 2022 results: revenue $850.0 million, net income $51.6 million, EPS $1.12. Guidance raised.

Period: nine months ended September 30, 2022
Revenue: $850.0 million
Net income: $51.6 million
EPS: $1.12
Guidance: raised
Result: reported results

Exact text from the filing

losses from recently acquired IPAs, which it believes to be more reflective of its business. Financial Highlights for Nine Months Ended September 30, 2022: • Total revenue of $850.0 million, up 47% from $578.8 million for the prior-year period • Net income attributable to ApolloMed of $51.6 million, compared to $60.1 million for the prior-year period • EPS-diluted

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Astrana Health, Inc. reported quarter ended September 30, 2022 results: revenue $317.0 million, net income $26.0 million, EPS $0.56. Guidance raised.

Period: quarter ended September 30, 2022
Revenue: $317.0 million
Net income: $26.0 million
EPS: $0.56
Guidance: raised
Result: reported results

Exact text from the filing

financial results for the third quarter and nine months ended September 30, 2022. Financial Highlights for Third Quarter Ended September 30, 2022: • Total revenue of $317.0 million, up 40% from $227.1 million for the prior-year quarter • Net income attributable to ApolloMed of $26.0 million, compared to $34.3 million for the prior-year quarter • Earnings

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Astrana Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028272

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.